INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

The safety profile of Bronchitol® (mannitol) is based on the safety data from Phase III clinical studies (including data from the initiation dose assessment).1

 

RESPIRATORY ADVERSE REACTIONS WITH BRONCHITOL DURING THE PHASE 3 STUDIES

aAdverse reactions that occurred only with the initiation dose assessment (MTT)

 

For the full list of Adverse Events, please see the UK Summary of Product Characteristics or the Ireland Summary of Product Characteristics.

A productive cough can contribute to sputum clearance.1

Following bronchodilator use and initiation dose assessment, the incidence of bronchospasm is low2,3


1. Bronchitol® Summary of Product Characteristics. Available online at https://www.medicines.org.uk/emc/medicine/26446. Accessed April 2019.
2. Bilton D, et al. Eur Respir J. 2011; 38: 1071-1080.
3. Aitken ML, et al. Am J Respir Crit Care Med. 2012; 185(6): 645-652.